Evaluation of Neoadjuvant Immune Combined Therapy and Traditional Neoadjuvant Therapy for Resectable Esophageal Cancer: A Systematic Review and Single-arm and Network Meta-analysis

Review question / Objective: Population: Patients with histologically-confirmed resectable esophageal carcinoma; Intervention: Neoadjuvant immunotherapy combined with chemotherapy or neoadjuvant immunotherapy combined with chemoradiotherapy followed by surgery; Control: Neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy followed by surgery; Outcomes: Treatment related adverse events, r0 resection rate, pathological complete response, major pathological response, objective response rate, disease control rate, postoperative complications, postoperative mortality, 1/2/3/5year overall survival, 1/2/3/5year disease free survival; Study Design: All prospective and restrospective studies.